Advertisement
Australia markets closed
  • ALL ORDS

    8,039.90
    +27.80 (+0.35%)
     
  • ASX 200

    7,796.00
    +26.60 (+0.34%)
     
  • AUD/USD

    0.6644
    -0.0015 (-0.23%)
     
  • OIL

    80.61
    -0.68 (-0.84%)
     
  • GOLD

    2,334.60
    -34.40 (-1.45%)
     
  • Bitcoin AUD

    96,577.20
    -1,173.20 (-1.20%)
     
  • CMC Crypto 200

    1,325.39
    -34.93 (-2.57%)
     
  • AUD/EUR

    0.6211
    -0.0006 (-0.09%)
     
  • AUD/NZD

    1.0852
    -0.0021 (-0.20%)
     
  • NZX 50

    11,682.39
    -89.42 (-0.76%)
     
  • NASDAQ

    19,700.43
    -51.87 (-0.26%)
     
  • FTSE

    8,237.72
    -34.74 (-0.42%)
     
  • Dow Jones

    39,150.63
    +15.87 (+0.04%)
     
  • DAX

    18,163.52
    -90.66 (-0.50%)
     
  • Hang Seng

    18,028.52
    -306.80 (-1.67%)
     
  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     

Sanofi (SNY) is a Great Momentum Stock: Should You Buy?

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Sanofi (SNY), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Sanofi currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

ADVERTISEMENT

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for SNY that show why this drugmaker shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For SNY, shares are up 0.39% over the past week while the Zacks Large Cap Pharmaceuticals industry is up 1.72% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 7.23% compares favorably with the industry's 9.94% performance as well.

Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Sanofi have increased 13.65% over the past quarter, and have gained 0.43% in the last year. On the other hand, the S&P 500 has only moved 4.43% and -5.9%, respectively.

Investors should also pay attention to SNY's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. SNY is currently averaging 1,929,997 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with SNY.

Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost SNY's consensus estimate, increasing from $4.40 to $4.45 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Given these factors, it shouldn't be surprising that SNY is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Sanofi on your short list.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research